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http://dx.doi.org/10.1016/j.jaip.2016.07.012interviews. Validation studies included 118 adults with CVID
who completed Short Form-36, Saint George Respiratory Ques-
tionnaire, General Health Questionnaire-12, and EuroQol-5D
questionnaire in a single session. Principal component and factor
analysis solutions identiﬁed 3 scores to be similar in number and
content for each solution. Validation of 3 factor scores was per-
formed by construct validity. Reproducibility, reliability,
convergent validity, and discriminant validity were evaluated.
Matrices consisting of correlations between the 32 items in the
CVID_QOL were calculated.
RESULTS: Factor analysis identiﬁed 3 dimensions: emotional
functioning (EF), relational functioning (RF), and
gastrointestinal and skin symptoms (GSS). The instrument had
good internal consistency (Cronbach’s alpha, min. 0.74 for GSS,
max. 0.84 for RF, n[ 118) and high reproducibility (intraclass
correlation coefﬁcient, min. 0.79 for RF, max 0.90 for EF,
n [ 27). EF and RF scores showed good convergent validity
correlating with conceptually similar dimensions of other study
scales. Acute and relapsing infections had a signiﬁcant impact on
EF and RF.
CONCLUSIONS: This study provides evidence of the reliability
and construct validity of the CVID_QoL to identify QoL issues
in patients with CVID that may not be addressed by generic
instruments.  2016 The Authors. Published by Elsevier Inc.
on behalf of the American Academy of Allergy, Asthma &
Immunology. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/). (J Allergy Clin Immunol Pract 2016;4:1169-79)Key words: Burden of disease; Common variable immune deﬁ-
ciency; CVID_QoL; Disease-speciﬁc questionnaire; Quality of
life; Questionnaire validation1169
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1170 QUINTI ETALAbbreviations used
BMI- Body mass indexCVID- Common variable immune deﬁciency
EF- Emotional functioningEQ-5D- EuroQol-5 dimensions questionnaire
GHQ-12- General health questionnaireGSS- Gastrointestinal and skin symptoms
ICC- Intraclass correlation coefﬁcient
MCS-Mental component summary
PAD- Primary antibody deﬁciency
PCS- Physical component summaryPhGA- Physician global assessment
PtGA- Patient global assessment
QoL- Quality of life
RF- Relational functioningSF-36- Short Form 36 questionnaire
SGRQ- Saint George Respiratory QuestionnaireTL- Trough levels
VAS- Visual analog scalePrimary antibody deﬁciency (PAD) is an umbrella term
encompassing a broad array of primary immunodeﬁciency dis-
eases collectively characterized by a quantitative and/or qualita-
tive impairment of antibody production. Common variable
immune deﬁciency (CVID) is the most common symptomatic
form of PAD.1 CVID includes a heterogeneous group of anti-
body deﬁciencies mostly of unknown etiology, frequently diag-
nosed in adults. Across the spectrum of clinical manifestations,
patients are frequently affected by severe and recurrent in-
fections, autoimmune disorders, granulomatous and inﬂamma-
tory diseases, and cancers.2
Improvements in awareness, prompt diagnosis, and the
introduction of immunoglobulin replacement therapy have
resulted in substantially extended life expectancy for patients
with PAD.3-5
Owing to this extended life expectancy, the qualitative patient
experience, frequently conceptualized as “quality of life” (QoL),
has become an important focus of clinical care and outcomes
research.6 QoL is a multidimensional concept that encompasses
the physical, psychological, and social aspects of well-being. Cen-
tral to this is that an individual’s perception of the impact of illness
on his/her life is often as important as (if not more important than)
clinical factors in predicting morbidity and mortality.7 Formal
QoL assessments, often made by administering patient-completed
questionnaires, have become a ubiquitous part of intervention and
patients’ outcome research, and are essential to guide efforts to
optimize the quality and outcomes of clinical care.
Many QoL measurement instruments (or “tools”) are available
and the decision to use one over another tool, to use a combi-
nation of 2 or more tools, should be driven by the purpose of the
measurement. The choice will depend on a variety of factors
including the characteristics of the population (eg, age, economic
status, language/culture), the environment in which the mea-
surement is undertaken (eg, clinical trial, routine physician visit),
and on the purpose of the assessment (eg, measuring changes
over time as in a natural history study vs clinical use to provide a
snapshot to supplement physician impression vs as an endpoint
to evaluate the effect of an intervention). These tools are essen-
tially used for research purposes, and very few initiatives intro-
duced such instruments in the clinical routine.To our knowledge, mainly generic health status QoL in-
struments have been used in adult populations affected by
CVID, and among them the Medical Outcomes Study in the
Short Form (SF-36 or SF-12) and the General Health
Questionnaire-12 Items (GHQ-12).8-10 However, generic QoL
instruments, by their nature, only include questions applicable to
a wide variety of populations and disease states, and may over- or
underestimate the true impact of CVID on an individual’s QoL.
The use of disease-speciﬁc tools is desirable to provide a more
accurate picture of the burden of each disease. Although disease-
speciﬁc tools have been developed for a variety of illnesses,11-13 to
our knowledge, there have been no studies to develop and
rigorously evaluate a disease-speciﬁc instrument for use in CVID
patient populations. Tools validated for other conditions such
the Saint George Respiratory Questionnaire (SGRQ) in use for
patients with lung diseases have been used in patients with
CVID.14 To address this need, our aim was to develop and
validate an acceptably short, cross-culturally valid, and reliable
instrument to measure QoL in adults with CVID.
METHODS
This single-center study was carried out in the Clinic for Adult
Immune Deﬁciency of Rome, Italy. Eligible patients were adults aged
18 years or older, with a diagnosis of CVID15 established 6 or more
months before enrollment and currently receiving intravenous or
subcutaneous immunoglobulin replacement therapy. Exclusions
included inability or unwillingness to provide written informed con-
sent or signiﬁcant medical or psychiatric illness that, in the opinion of
the treating clinician, precluded participation. All patients enrolled
provided their informed consent. The Ethical Board of the Sapienza,
University of Rome approved this study. The portion performed at
Texas Children’s Hospital was approved by the Institutional Review
Board for the protection of human subjects at Baylor College of
Medicine. The study design is summarized in Figure 1.
Instrument development
The content of the CVID_QoL questionnaire was based on
qualitative focus groups and individual patient interviews conducted
in the clinic for primary immune deﬁciencies in Rome. Three in-
dependent focus groups were managed with patients with CVID
(including a total of 28 patients) and an expert panel consisting of a
nurse, a doctor, and a psychologist, each with expertise in primary
immunodeﬁciency care. These sessions elicited an open discussion of
the most relevant issues affecting the patient’s personal experience
with disease. A list of 56 items thought to be of most concern to
patients was assembled. The number of items was reduced to 32
after ranking items in descending order and selecting the highest-
ranking items for inclusion. Study psychologists conducted struc-
tured interviews with other patients with CVID recruited in 2
consecutive days (5 patients per day) who had not participated in
any of the focus groups to evaluate general readability of each item
and its answer choices and to reﬁne the wording and order of the
questions. In the ﬁnal questionnaire, negatively worded items were
avoided and response options were formulated using a 5-point scale,
with 0 ¼ “never” and 4 ¼ “always,” with higher values generally
indicating increasing disability. The ﬁnal version of the CVID_QoL
questionnaire is shown in Figure E1 (available in this article’s Online
Repository at www.jaci-inpractice.org).
An English translation of the questionnaire was also obtained
following the 3 phases described by the guidelines for the translation
and cultural adaptation of health-related QoL measures.16,17 During
Testing the CVID_QoL
INTERVENTIONAL, CROSS-SECTIONAL, COHORT STUDY 
Formulation of CVID_QoL Questionnaire
Open and registered discussion with the team nurse, a doctor and 
psychologists on the most relevant issues related to physical, mental 
and social behavior aspects to define 1) items ; 2) 5 point answers 
for each question.  A list of 56 items thought to be of most concern to 
patients was completed. 
Individual interview to determine the correct understanding of the 
question s and specific terms used
Item selection
(28 patients)
T0
Comprehension
(10 patients)
Self-administration of CVID_QoLReproducibility
(27 patients)
T1 Self-administration of CVID_QoL
Inclusion criteria:
1) CVID diagnosis; 
2) >18 years; 
3) time since diagnosis >6 months; 
Age, gender, education, number of infections in the last 3 and 12 
months (self-reported), type of Ig, IgG TL, BMI (from medical 
files), acute respiratory  or gastro-intestinal infection; PhGA.
Enrollment
(118 patients)
Data collection
Individual (self) administration of CVID_QoL. At the same setting
(self) administration of SF-36, SGRQ, GHQ-12, EQ-5D; PtGA. 
Questionnaires
administration
Data analysis
Reduction of the item to 32 after ranking items n descending order 
and selecting the highest-ranking items for inclusion
Item reduction
Exclusion criteria: 
inability to provide written informed 
consent; significant medical/psychiatric 
illness precluding participation. 
Translation in to English of CVID_QoL
Two translators produce two independent English version from the 
Italian questionnaire, and  then discuss to agree on a “pooled” 
version. 
Individual interview to English-speaking patients determine the 
correct comprehension of the questions.
First translation
Plot test
(5 patients)
Two translators retranslate the version back into Italian language. Back 
translation
T0 Self-administration of CVID_QoL
T1 Self-administration of CVID_QoL
Reproducibility
(30 patients)
Data analysis
FIGURE 1. Study design to develop and validate a questionnaire to measure health-related quality of life of adults with common variable immune deficiency. BMI, Body mass index; CVID,
common variable immune deficiencies; EQ-5D, EuroQol-5 dimensions questionnaire; GHQ-12, Global Health Questionnaire; PAD, primary antibody deficiency; PtGA, patient global
assessment; QoL, quality of life; SF-36, Short Form 36 questionnaire; SGRQ, Saint George Respiratory Questionnaire; TL, IgG trough level.
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1172 QUINTI ETALphase 1, 2 English mother-tongue translators produced 2 indepen-
dent versions, which were compared and discussed to agree on a
“pooled” version. In phase 2 (back-translation), 2 independent
translators retranslated the version back into the original language,
without having access to the original version. Phase 3 involved
administering the questionnaire to 5 English-speaking patients with
CVID enrolled from the adult CVID population followed at Texas
Children’s Hospital, to assess comprehension of each translated
item. The English version of the CVID_QoL questionnaire is shown
in Figure E2 (available in this article’s Online Repository at www.
jaci-inpractice.org). The validation process did not include the 5
English-speaking patients with CVID. Further studies in progress
will allow for the analysis of the cross-cultural validity of the English
version of the CVID_QoL instrument.
Instrument validation
To validate the questionnaire, established adult patients with
CVID not involved in the focus groups nor in the preliminary
structured interviews were recruited from the entire cohort of adult
CVID clinics in Rome, Italy, between January and April 2015
(Figure 1). One hundred and twenty-seven patients with CVID
considered eligible for the study were consecutively approached; nine
declined to participate. To evaluate reproducibility, 27 patients were
randomly selected to complete the measures in a desired time frame
of 20-30 days after baseline.
Demographic and clinical characteristics
Participants reported demographic characteristics, including age, sex,
and highest level of education completed. Theywere also asked to report
the number of infections they had experienced within the 3 and 12
months before participation. Clinical data were abstracted from the
medical record, including the date of CVID diagnosis (used to calculate
duration of disease), immunoglobulin levels at the timeofdiagnosis, IgG
trough levels (TL), current body mass index (BMI), presence of bron-
chiectasis by computed tomography scan, and chronic diarrhea deﬁned
as abnormal frequency andﬂuidity of fecal evacuations lastingmore than
1 month in the year preceding the study.18
The reported number of infections within the previous 3 and 12
months was cross-validated by clinicians’ review of clinical records.
The physicians also rated their perception of disease severity for each
patient at the time of the evaluation (physician global assessment, or
PhGA).
Questionnaires
After providing informed consent, patients completed question-
naire packets including the following questionnaires administered in
this sequential order: CVID_QoL, the SF-36, the SGRQ, the
GHQ-12, the EuroQol-5 dimensions questionnaire (EQ-5D), and a
patient global assessment (PtGA). All participants were given the
questionnaires to complete in the clinic waiting room before meeting
with their physician.
SF-36. The SF-36 questionnaire is a self-administered question-
naire; it includes 36 items in a Likert-type or forced-choice format
and measures health on 8 multi-item dimensions: physical func-
tioning, role-physical, bodily pain, general health, vitality, social
functioning, role-emotional, and mental health.19 Scores for each
dimension range from 0 to 100, with higher scores indicating better
health. Two summary measures, the physical component summary
(PCS) and mental component summary (MCS), cross-culturally
validated in the framework of the International QoL Assessment
project for the Italian version of the SF-36 were generated.20 BecauseSF-36 is designed to assess the deterioration of the health status, we
expected to observe inverse correlations with the CVID_QoL items.
SGRQ. The SGRQ is a self-administered, 50-item questionnaire
that measures the respiratory-speciﬁc health status.21 The items are
divided into 3 dimensions: “symptoms,” “activities,” and “impacts”
of disease on activities of daily living. The total score and individual
dimension score range from 0 to 100. The higher the score, the
worse the QoL.
GHQ-12. The GHQ-12 is a self-administered, 12-items ques-
tionnaire, designed to measure psychological distress and to detect
current nonpsychotic, psychiatric disorders, such as depression and
anxiety.22 Answers are given on a 4-point scale. When scored with
the binary method (0e0e1e1), the GHQ-12 can be used as a
screening tool yielding ﬁnal scores that range from 0 to 12. Oper-
ationally, patients scoring 4 or more were considered as “GHQ-
positive (GHQþ)”/at risk of anxiety and depression.23
EQ-5D. The EQ-5D is a self-administered questionnaire, con-
sisting in a descriptive system with 5 dimensions (“mobility,” “self-
care,” “usual activities,” “pain/discomfort,” “anxiety/depression”)
and a visual analog scale (VAS).24 In the descriptive system, for each
dimension, the answers are coded with a 1-digit number from “1”
(“no problems”) to “5” (“extreme problems”). The digits of the 5
dimensions are combined into a 5-digit number, which describes the
overall health state of the respondent.25 The EQ VAS is a VAS with
endpoints labeled “the best health you can imagine” (“100”) and
“the worst health you can imagine” (“0”): subjects had to write the
number marked in the scale on a box.
Physician and patient global assessments. The PhGA
and the PtGA consisted of the following questions respectively: for
PhGA “In your opinion, compared to other patients with the same
condition, how severe is the disease of patient X?” and for PtGA “In
your experience, how severe is your disease?”. Answers were given on a
5-point scale from 0: “very mild,” 1: “mild,” 2: “moderate,” 3:
“severe,” and 4: “very severe.” The PhGA was completed by the
physician at the end of the clinical outpatient visit. The PtGA was
completed, as were other questionnaires, before meeting the physician.
Analyses
Patient demographics and clinical characteristics are summarized
by frequencies and percentages, and means and standard deviations
where appropriate.
We generated descriptive, comparative analyses of CVID_QoL
Global scores by demographic and clinical characteristics of study
participants. The CVID_QoL Global score was deﬁned as the sum
of all scores of each item (possible range: 0-128), and it was trans-
formed as a percentage of the maximum possible score. For example,
a score of 64 would correspond to 50 on the transformed scale. The
same transformation, eventually, was performed for all the di-
mensions resulting from the factor analysis. When up to 3 answers
were missing in a given dimension, the score of the missing items
was imputed as the average scores of the items in the same dimen-
sion. When more than 3 items in the same dimension were missing,
the whole dimension was considered as missing.
We evaluated the factorial structure of the CVID_QoL to
identify the main dimension underlying the items. For the factor
analysis, we utilized the principal component method and principal
axis factoring and determined how many factors to extract using
Cattell’s screen test.26,27 Reproducibility by the intraclass correlation
TABLE I. Comparisons of mean values of CVID_Qol Global, EF, RF, GSS scale scores by categories of patient characteristics for 118 adult
patients with CVID
n (%) CVID_QoL Global
Emotional
functioning (EF)
Relational
functioning (RF)
Gastrointestinal and skin
symptoms (GSS)
Sex
Male 46 (39) 25.7 (14.2) 28.5 (15.9) 20.4 (13.1) 24.2 (19.5)
Female 72 (61) 31.3 (16.4) 34.4 (17.6) 26.4 (19.2) 27.5 (21.9)
P value ns* ns* ns* ns*
Age
 50 y 66 (56) 26.5 (15.5) 29.3 (17.4) 21.4 (15.9) 24.6 (20.3)
> 50 y 52 (44) 32.6 (15.7) 35.7 (16.4) 27.5 (18.4) 28.2 (21.8)
P value .04* .04* ns* ns*
BMI
18.5 9 (7) 41.1 (11.4) 47.8 (12.3) 31.5 (16.7) 40.3 (22.1)
18.6-24.9 67 (57) 28.2 (15.8) 31.0 (16.4) 24.2 (17.3) 24.2 (22.5)
25 42 (36) 28.0 (15.9) 31.1 (18.3) 22.3 (17.7) 26.5 (17.1)
P value .02† .004† ns† .05†
Highest level of education completed
<13 y 31 (26) 32.1 (17.5) 35.2 (19.4) 28.3 (19.9) 25.9 (17.3)
 13 y 87 (74) 28.3 (15.3) 31.2 (16.5) 23.0 (16.3) 26.6 (22.2)
P value ns* ns* ns* ns*
BMI, Body mass index; CVID, common variable immune deﬁciency; ns, not statistically signiﬁcant; QoL, quality of life.
CVID_QoL Global, EF, RF, and GSS scores expressed as percentages were presented as mean (SD).
*P values were calculated by the t-test.
†P values were calculated by ANOVA.
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CVID_QoL by using Cronbach’s alpha and Pearson’s correlation
and convergent validity by examining Pearson’s correlations between
the CVID_QoL Global, CVID_QoL dimensions scores, and
existing QoL measures were evaluated. Discriminant validity was
assessed by comparing scores between subsets of patients. CVID_-
QoL scores between groups with chronic diarrhea against those
without diarrhea were evaluated by Student’s t-test. We also
compared CVID_QoL scores between patients grouped according
to the number of infectious episodes within 3 (0-1, >1) and 12
months (0-1, 2-6, >6) before enrollment, by Student’s t-test and
ANOVA, respectively.
The statistical signiﬁcance was set at the conventional level of
P < .05. All statistical analyses were performed using the statistical
package Stata 11 (Stata Corp., College Station, Tex) and GraphPad5
(GraphPad software, San Diego, Calif, www.graphpad.com).RESULTS
Participant characteristics
One-hundred and eighteen consecutive patients with CVID
provided informed consent and participated in the study. De-
mographic data and clinical characteristics are summarized in
Table I. The majority of patients were female (n ¼ 72, 61%).
The mean duration of disease was 12.1  10.7 years. All patients
were on Ig replacement therapy, with 89% receiving intravenous
Ig replacement therapy. The mean TL of Ig at the time of the
study was 663  158 mg/dL. The average number of reported
infections in the 3 and 12 months preceding the test was
1.4  1.5 and 4.2  3.8 episodes, respectively. Patients involved
in focus groups and structured interviews had similar de-
mographic and immunological characteristics to the overall
CVID cohort attending our center (data not shown).Instrument characteristics
Feasibility. All (n ¼ 118) patients completed the 32-item
CVID_QoL questionnaire, which required approximately 10 to
15 minutes for completion. The missing response rate was 2.0%
for all questionnaire items. Table I displays baseline scores by age,
sex, and BMI. Patients older than 50 years had signiﬁcantly worse
CVID_QoL Global and emotional functioning (EF) scores. No
difference was observed between males and females and between
patients with higher or lower education level. Patients with lower
BMI (18.5) had a higher CVID_QoL Global score in compar-
ison with those having normal and/or high BMI. No correlation
was appreciated between the CVID_QoL score and IgG, IgA, and
IgM serum levels at diagnosis and IgG TL at the time of the study,
suggesting that immunoglobulin serum levels have a low impact on
QoL that is a complex measurement inﬂuenced simultaneously by
many factors.
Factor analysis. Factor analysis (Table II) with varimax
rotation yielded a 3-factor model: EF, relational functioning
(RF), and gastrointestinal and skin symptoms (GSS), together
accounting for 72% of the variance. EF includes 19 items, RF
includes 9 items, and GSS includes 4 items. Loadings ranges
were EF: 0.31-0.77; RF: 0.34-0.72; GSS 0.33-0.71. Cough was
included in the relational dimension (RF), whereas gastrointes-
tinal manifestations and skin diseases went together in a separate
dimension (GSS). The CVID_QoL dimensions identiﬁed by
factor analysis are represented in Figure 2. The average
CVID_QoL Global score was 29  16.5%. Scores observed in
each dimension were EF: 32.4  17.5% (range: 0% to 82.9%),
RF: 17.5  32.4% (range: 0% to 84.4%), GSS: 26  21%
(range: 0% to 75%). A total of 32% of patients had a
CVID_QoL Global  20%, 44% had a CVID_QoL Global
ranging from 20% to 40%, and 21% had a CVID_QoL Global
TABLE II. Principal component analysis* of the CVID_QoL and loading for the 3 dimensions and for each item
CVID_QoL items
Dimension 1: Emotional
functioning (EF)
Dimension 2: Relational
functioning (RF)
Dimension 3: Gastrointestinal
and skin symptoms (GSS)
1 Sadness 0.61
2 Dietary changes 0.71
3 Anger 0.41
4 Diarrhea 0.69
5 Difﬁculty planning 0.56
6 Cough 0.34
7 Unable to provide care 0.58
8 Health exacerbation 0.77
9 Joint pain 0.56
10 Needing help 0.58
11 Run out of medications/immunoglobulins 0.47
12 Afraid of an adverse reaction 0.55
13 Concerned about the future 0.77
14 Limited by diarrhea 0.68
15 Loss of autonomy 0.61
16 As contagious 0.68
17 Difﬁculty in usual activities 0.52
18 Fear of death 0.43
19 Limited by cough 0.72
20 Isolated 0.57
21 Fear of illness 0.55
22 Weakness 0.66
23 Difﬁculty in sexual relations 0.59
24 Bothered by immunoglobulins 0.31
25 Limitation on leisure activity 0.59
27 Difﬁculty in relationships 0.69
28 Perception as sick 0.72
29 Embarrassed 0.49
30 Becoming infected 0.47
31 Troubled by other patients 0.36
32 Tired 0.56
CVID, Common variable immune deﬁciency; QoL, quality of life.
Each item is indicated as the number of the question, followed by an indicative word of the sentence, that is, 1 Sadness: question number 1: I felt sad.
*Principal components method with varimax rotation; rotation converged in 7 iterations.
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Global scores is represented in Figure 3.
Reproducibility. There were no signiﬁcant differences in the
ﬁrst and second assessment scores. Of the 27 patients evaluated
for reproducibility, values of agreement were very satisfactory:
EF, ICC ¼ 0.90 (95% CI 0.80-0.95); RF, ICC ¼ 0.79 (95% CI
0.59-0.90); GSS, ICC ¼ 0.85 (95% CI 0.71-0.93). All P values
were <.001.
Reliability. A strong internal consistency of each disease-
speciﬁc dimensions (>0.7) with an alpha coefﬁcient of 0.82,
0.84, and 0.74 for the EF, RF, and GSS subscales, respectively.
Convergent validity. Correlations between the Global and
dimensions of CVID_QoL and those of each of the 5 additional
instruments applied to our patients with CVID as well as the
instrument dimensions are reported in Table III.
SF-36. Statistically signiﬁcant correlations were found between
the EF dimension and the SF-36 PCS and MCS summarymeasures (0.55 and 0.49); the RF dimension and the SF-
36 PCS and MCS summary measures (0.52 and 0.40);
and between the GSS dimension and the SF-36 summary
score MCS (0.38).
SGRQ. EF and RF were positively related to the total SGRQ
score (0.52 and 0.54, respectively) and to all SGRQ di-
mensions, showing that the respiratory problems impact the
health-related QoL of CVID, as recently demonstrated.14 As
expected, the GSS dimension was not related to the SGRQ
score.
GHQ-12. GHQ-12 was strongly related to the EF (0.74), RF
(0.50), and GSS (0.33) dimensions.
EQ-5D. The EF, RF, and GSS dimensions were related to
EQ-5D VAS (0.68, 0.52, 0.32). EF and RF were
also related to all EQ-5D components (mobility, usual
activities, self-care, pain, and anxiety), whereas GSS was
related to usual activity, pain, and anxiety dimensions
(Table III).
FIGURE 2. CVID_QoL dimensions identified by factor analysis. Each item is indicated as the number of the question, followed by an
indicative word summarizing the sentence, that is, 1 Sadness ¼ question number 1: I felt sad. CVID, Common variable immune defi-
ciency; EF, emotional functioning, GSS, gastrointestinal and skin symptoms; QoL, quality of life; RF, relational functioning.
FIGURE 3. Distribution of the 118 CVID_QoL Global scores.
Patients were grouped according to their CVID_QoL Global score.
CVID, Common variable immune deficiency; QoL, quality of life.
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QUINTI ETAL 1175PhGA and PtGA. A total of 7% of the patients perceived
their health status as “very mild/mild,” 37% as “moderate,”
49% as “severe,” and 7% as “very severe.” EF, RF, and GSSscores correlated only with PtGA (0.56, 0.43, 0.27). Only RF
correlated with PhGA (0.25). As also demonstrated in our
previous work,6 the correlation between PtGA and PhGA was
low (0.21).
Discriminatory validity. The experience of acute and re-
lapsing infections had a signiﬁcant impact on CVID_QoL.
Patients reporting a low number of infections (0-1) in the 3
months preceding the study time had lower scores than patients
reporting more than 1 infection (Figure 4, A). A close rela-
tionship between the number of infections and the CVID_QoL
scores was even more evident when the number of infections in
the year preceding the study was analyzed (Figure 4, B).
Differently from the Global, EF, and RF scores, the number of
infections did not affect the GSS score. This ﬁnding was not
unexpected in that acute and relapsing infections were mainly
respiratory, whereas diarrhea and skin diseases were mainly
chronic conditions. Moreover, patients with CVID with
chronic diarrhea had a worse CVID_QoL score than patients
without chronic diarrhea (36.4  16.0% vs 26.4  15.1%,
P ¼ .004) and a worse GSS (39.5  20.7% vs 21.6  19.7%,
P < .0001).
The overall burden of disease was assessed by the analysis of
items with the highest and lowest impact on QoL as reported
by the entire CVID population. The percentage of patients
TABLE III. Correlations of the CVID_QoL scores with the SF-36, SGRQ, GHQ-12, EQ-5D scores
CVID_QoL Global
Emotional
functioning (EF)
Relational
functioning (RF)
Gastrointestinal and skin
symptoms (GSS)
SF-36
Physical functioning 0.49** 0.47** 0.47** 0.16 (ns)
Role-physical 0.77** 0.76** 0.57** 0.46**
Bodily pain 0.56** 0.52** 0.43* 0.45**
General health 0.68** 0.67** 0.56** 0.33*
Vitality 0.63** 0.64** 0.45** 0.34*
Social functioning 0.30* 0.30* 0.23 (ns) 0.12 (ns)
Role-emotional 0.58** 0.57** 0.43* 0.41*
Mental health 0.51** 0.51** 0.34* 0.34*
Physical component summary (PCS) 0.57** 0.55** 0.52** 0.23 (ns)
Mental component summary (MCS) 0.52** 0.49** 0.40 0.38
SGRQ
Total 0.53** 0.52** 0.54** 0.09 (ns)
Symptoms 0.45* 0.45* 0.48* 0.03 (ns)
Activity 0.50** 0.49* 0.51** 0.13 (ns)
Impact 0.48* 0.48* 0.49* 0.06 (ns)
GHQ-12 continuous 0.74** 0.74** 0.50** 0.33*
EQ-5D
VAS 0.65** 0.68** 0.52** 0.32**
Mobility 0.32** 0.36** 0.25* 0.06 (ns)
Self-care 0.24* 0.25* 0.20* 0.05 (ns)
Usual activity 0.59** 0.60** 0.51** 0.25*
Pain discomfort 0.53** 0.57** 0.36** 0.27*
Anxiety/depression 0.41** 0.43** 0.31** 0.21*
PGA
PtGA 0.53** 0.56** 0.43** 0.27*
PhGA 0.17 (ns) 0.13 (ns) 0.25* 0.06 (ns)
CVID, Common variable immune deﬁciency; EQ-5D, EuroQol 5 dimensions; GHQ-12, General Health Questionnaire 12 Items; ns, not statistically signiﬁcant; PGA, physician
(PhGA)/patients (PtGA) global assessment; QoL, quality of life; SF-36, Short Form 36 questionnaire; SGRQ, Saint George Respiratory Questionnaire; VAS, visual analog scale.
*P < .01.
**P < .001.
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each item is shown in Table IV. The highest frequencies
(25%) were observed for symptoms such as cough, asthenia,
joint pain, and diarrhea, and for problems related to short- and
long-term planning of their activities. The lowest frequencies
(10%) were reported for problems related to immunoglob-
ulin treatment and to the embarrassment to other patients,
relatives, or unfamiliar persons due to different aspects of
CVID.
DISCUSSION
Personalized care planning used in the management of chronic
conditions should take advantages of discussions between
patients and clinicians to identify critical issues related to the
patient’s illness. QoL is an important and established health care
outcome depicting the impact of illness and treatment on the
patient’s personal experience. Clarity in understanding aberra-
tions in QoL, and the speciﬁc factors of the disease that drive it,
will contribute to empowering health care providers to target
improvements for their patients.
Questionnaires such as the SF-36 have been designed for the
evaluation of the health status in the general population.19,20
However, speciﬁc and disease-related measurements to assessthe burden of disease in patients with PAD have not been
standardized nor validated as they have been in many other
medical conditions. Several disease-speciﬁc questionnaires may
have some utility in patients with PAD given the clinical spec-
trum and include the SGRQ,21 the Inﬂammatory Bowel Disease
Questionnaire,11 and the Asthma Quality of Life Question-
naire.12 A recent study in PAD used a generic tool (SF-36) in
combination with a disease-speciﬁc tool (SGRQ) and demon-
strated that much of the QoL impact in PAD was related to
respiratory involvement, speciﬁcally the severity of airﬂow
obstruction, respiratory exacerbation frequency, and dyspnea.14
Although the information obtained from a general QoL in-
strument is of value in PAD, the advantages of using multiple
tools simultaneously were demonstrated in 2 separate publica-
tions from our group. In the ﬁrst study,6 we used generic
instruments (SF-36 and GHQ-12) to assess the health-related
QoL. Mental health scales of SF-36 were less affected than
physical scales and that being female, older, GHQ-positive, and
alexithymic were major risk factors for poor health
status. Approximately one-third of patients were at risk of anx-
iety and/or depression (two-thirds of females), and GHQ-
positive patients had a greater burden of disease, suggesting
the need for counseling. In a more recent study, we conﬁrmed
FIGURE 4. Number of infections and CVID_QoL scores. Patient
groups were selected according to the number of self-reported
episodes of infections in the 3 (A) and in the 12 months (B) pre-
ceding the study time. P values were calculated using the t-test
and ANOVA. CVID, Common variable immune deficiency; EF,
emotional functioning; GSS, gastrointestinal and skin symptoms;
QoL, quality of life; RF, relational functioning.
TABLE IV. Questions referred as grade 3 “often” or grade 4
“always” by  25% (a) or 10% (b) by the entire CVID population
(a) Item no. Question Percent
6 I had a cough and/or phlegm 55
32 I felt tired 47
9 I had discomfort and/or pain in my joints 36
5 I had to give up making long-term plans 30
8 I was afraid that my health might worsen 29
2 I had to change my diet 26
4 I had diarrhea 25
13 I was concerned about my future 25
17 It was hard to do my usual work/studies 25
21 I was afraid of getting sick 25
(b) Item no. Question Percent
31 I felt troubled by relationships with other
patients who have the same disease
0
27 I found it difﬁcult to relate to people I
spend time with
3
16 I was afraid I might make others sick
with my infections
4
18 I was afraid of dying 5
26 I felt uncomfortable because of my skin problems
(spots, redness, rashes, infections)
5
10 I needed help taking care of myself 6
29 I was embarrassed 6
12 I was afraid of adverse reactions to i
mmunoglobulin therapy
7
19 I avoided leaving the house because of my cough 7
11 I was afraid I would run out of medication and/or
immunoglobulin treatments
8
14 I avoided leaving my home because of diarrhea 8
20 I tended to isolate myself 8
23 My sexual activity was affected 9
CVID, Common variable immune deﬁciency.
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with other questionnaires increased the possibility to identify
correct measures for intervention and the potential to intervene
to reduce disease burden.10 Although the purpose of the general
QoL instruments is in part to allow cross-comparison amongst
diseases and distinct patient groups, the need to potentially
administer multiple instruments to patients with PAD to most
accurately deﬁne the QoL signal suggests the need for more
speciﬁc measures for the PAD population.
With the aim of more accurately characterizing the PAD
patient experience, we developed and validated a single disease-
speciﬁc QoL tool for adults with CVID, the CVID_QoL
questionnaire, potentially able to capture known disease-speciﬁc
nuances that affect the burden of disease in CVID. Our objective
for the CVID_QoL was to be able to assess the dimensions of the
CVID experience, which may not be captured by existing
instruments.
This study provides evidence of the reliability and constructs
validity of the CVID_QoL instrument to assess health-related
QoL in adult patients with CVID.
The CVID_QoL questionnaire takes approximately 10 to 15
minutes to complete and can be used to identify QoL issues that
may not be addressed in generic QoL instruments or during
routine patient encounters. The instrument had high internal
consistency and high test-retest reliability.
The structure of the CVID_QoL and that of its dimensions
were conﬁrmed by factorial analysis: the ﬁnal 32 items wereorganized into 3 dimensions: EF, RF, and GSS. Although res-
piratory symptoms were grouped within the relational and
emotional dimensions, gastrointestinal and skin signs were
considered as a separate dimension by factorial analysis. The
relevance of the latter was conﬁrmed by the clinical data showing
a high impact of gastrointestinal diseases in CVID and a poor
response to treatments.28-30
The highest impact within the CVID_QoL as self-reported by
our patients was attributable to symptoms such as cough,
asthenia, joint and muscle pain, diarrhea, and to problems related
to short- and long-term planning of their activities. The lowest
impact on reported health within the CVID_QoL was attrib-
utable to problems related to immunoglobulin treatment and to
any embarrassment to other patients, relatives, or third parties.
The low self-reported impact of Ig treatment in comparison with
that of the disease manifestations themselves might explain the
different results obtained by studies on QoL targeted to the
analysis of treatment burden, without taking into account the
overall disease load.30-32
Overall, correlations with the other questionnaires (SF-36,
SGRQ, GHQ, and EQ-5D) were found. In particular, the
emotional dimension (EF) was related to the comparable di-
mensions of SF-36, whereas the relational dimension (RF) was
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dimension was related to the GHQ-12 score and to the
dimension “activity/pain/discomfort” of the EQ-5D.
CVID_QoL and all its dimensions were also strongly related
to overall burden and psychological well-being, as shown by the
correlation with VAS EQ-5D and GHQ-12. The high correla-
tion between CVID_QoL Global and its dimensions EF and RF
with activity and impact scales of SGRQ demonstrated that the
respiratory complications in CVID affected both the relational
and the emotional areas.
All these data allowed us to conclude that CVID_QoL was
able to identify broad characteristics relevant to patients with
CVID and potentially capture signals speciﬁc to some but not all
the general QoL instruments.
All dimensions correlated with PtGA and not with PhGA, and
as we have already demonstrated in our previous work,10 the
correlation between PtGA and PhGA was low. This reinforces
the concept that the use of a patient’s reported outcome in-
strument is advisable in both research activities and clinical
practice to truly deﬁne outcomes of relevance to patients with
CVID.
Although the present study was focused on the cross-
validation of the CVID_QoL, it was not designed to demon-
strate superiority or improved utility compared with other tools.
In this evaluation study, the entire cohort of patients attending
our center were involved to minimize bias in the selection of the
study population. Thus, it is difﬁcult to presently compare our
data with other studies in which stronger selection factors might
have shaped the composition of the sample. In a recent paper33
on perceived health in patients with primary immune deﬁciencies
by the Immune Deﬁciency Foundation, factors driving perceived
health status were educational level, age, acute and chronic dis-
eases, hospitalization, limitation in the physical activities, “on
demand” access to specialist care, the specialty of physician caring
the patients, and regular Ig replacement therapy. We did not ﬁnd
any correlation between the CVID_QoL score with educational
level and Ig treatment (although all of our patients were receiving
Ig treatment) while we conﬁrmed factors such as age and number
of acute infections in patients affected by chronic illnesses.34,35
Particularly, the number of infections in our study was self-
reported but also cross-validated by clinical records and it rep-
resented an important factor for the higher CVID_QoL score.14
We recommend the widespread use of the CVID_QoL and its
integration into research and clinical care, but appreciate that
further investigation is required. It will be important to evaluate
the performance of this instrument among larger numbers of
patients across the continuum of age, disease activity, disease
severity, duration, disability, and other PAD diagnoses to
develop normative PAD data. It is also important to evaluate its
performance in relevant subgroups and to demonstrate that the
instrument is sufﬁciently responsive or sensitive to disease status
changes over time. Similarly, the impact of treatment alterations
on the CVID_QoL score is presently unclear, but we are hopeful
that the additional focus on disease burden relevant to patients
with CVID will allow for the highest resolution of measuring
change. The additional studies of application of CVID_QoL in
English as well as evaluation of its overall clinical utility, feasi-
bility, and responsiveness to clinical status change are currently in
progress. We are hopeful that this well-performing QoL tool can
be used to supplement existing approaches to provide additional
resolution in CVID regarding the perception that patients haveof their well-being. The ability to better discern the impact of a
clinical intervention or an early signal of exacerbation will
hopefully help guide better clinical decisions and patient care.Acknowledgments
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FIGURE E1. The Italian version of the CVID_QoL questionnaire. CVID, Common variable immune deficiency; QoL, quality of life.
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FIGURE E2. The English version of the CVID_QoL questionnaire. CVID, Common variable immune deficiency; QoL, quality of life.
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